New Data Available for GSD1a, OTC Deficiency, and Wilson Disease Studies
In a recent press release, biopharmaceutical company Ultragenyx Pharmaceutical Inc. (“Ultragenyx”) shared positive safety and efficacy data from Phase 1/2 clinical trials on gene